8-K filed Nov 4, 2026 at 16:16 ET
Bio-Rad reported Q3 2026 non-GAAP EPS of $2.65, beating the $2.23 consensus by 18.8%, and revenue of $656.4M, slightly above the $650.0M estimate. Non-GAAP operating margin expanded 100bps YoY to 12.8%, and the company maintained its full-year 2026 guidance for currency-neutral revenue decline of 3.0% to growth of 0.5% and non-GAAP operating margin of 10.0-12.0%. GAAP results included a $49.8M impairment charge and $77.2M in restructuring costs, driving a GAAP operating loss.